89Zr-DFO-girentuximab Expanded Access Program (EAP)
Public ClinicalTrials.gov record NCT06090331. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Expanded Access Program for the Non-invasive Detection of Clear Cell Renal Cell Carcinoma (ccRCC) in Patients With Renal Masses Utilizing 89Zirconium-labelled Girentuximab (89Zr-DFO-girentuximab)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this Expanded Access Program (EAP) is to enable the use of 89Zr-DFO-girentuximab with positron emission tomography/computed tomography (PET/CT) imaging to non-invasively detect carbonic anhydrase 9 (CAIX)-expressing clear cell renal cell carcinoma (ccRCC) in patients with renal masses as determined by conventional imaging.
Study identification
- NCT ID
- NCT06090331
- Recruitment status
- No Longer Available
- Study type
- Expanded access
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- May 28, 2026
United States locations
- U.S. sites
- 22
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arkansas Urology | Little Rock | Arkansas | 72211 | — |
| UCLA | Los Angeles | California | 90095 | — |
| Stanford Urologic Cancer Program | Palo Alto | California | 94304 | — |
| University of Florida College of Medicine Jacksonville | Jacksonville | Florida | 32209 | — |
| Biogenix Molecular | Miami | Florida | 33165 | — |
| Sarasota Memorial Health Care System | Sarasota | Florida | 34243 | — |
| Indiana University | Bloomington | Indiana | 47405 | — |
| Kansas University Medical Center | Kansas City | Kansas | 66103 | — |
| United Theranostics | Glen Burnie | Maryland | 21061 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Munson Medical Center | Traverse City | Michigan | 49684 | — |
| M Health Fairview/ University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Xcancer | Omaha | Nebraska | 68130 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Kettering Health Main Campus | Kettering | Ohio | 45429 | — |
| Urology Associates, PC | Nashville | Tennessee | 37209 | — |
| Austin Radiological Association | Austin | Texas | 78705 | — |
| UT Southwestern | Dallas | Texas | 75390 | — |
| MD Anderson Cancer Center | Houston | Texas | 77054 | — |
| Urology San Antonio | San Antonio | Texas | 78229 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06090331, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 28, 2026 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06090331 live on ClinicalTrials.gov.